JHS Svendgaard Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
JHS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
JHS Svendgaard Laboratories reported Q1 FY26 (quarter ended June 30, 2025) standalone revenue from operations of ₹2,345.41 lakhs, down about 4.2% from ₹2,448.39 lakhs in Q1 FY25, though other income rose sharply to ₹99.83 lakhs. The company swung to a net profit of ₹105.57 lakhs versus a loss of ₹62.80 lakhs in the year-ago quarter, with EPS of ₹0.12. Total income stood at ₹2,445.24 lakhs versus ₹2,480.39 lakhs. The board also approved the appointment of V.K. Khosla & Co. as statutory auditors for five years (FY26–FY30) and M/s Dahiya & Associates as secretarial auditors, and reconstituted the Audit Committee after Mr. Mukul Pathak's tenure ended. Additionally, the ESOP Scheme 2025 was deferred for a comprehensive review.
The swing to profitability and continued operations are positives, but a slight revenue decline and the deferral of the ESOP scheme introduce some uncertainty. Shareholders should note the change in statutory auditor and the pending utilisation of ₹1,366.21 lakhs from the August 2024 preferential issue still parked in fixed deposits.